Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cutaneous melanoma (CM) is a malignant tumor formed from pigment-producing cells called melanocytes. It is one of the most aggressive and fatal forms of skin malignancy. In the last decades, CM's incidence has gradually risen, with 351,880 new cases in 2015. Since the 1960s, its incidence has increased steadily, in 2019, with approximately 96,000 new cases. A greater understanding of early diagnosis and management of CM is urgently needed because of the high mortality rates due to metastatic melanoma. Timely detection of melanoma is crucial for successful treatment, but diagnosis with histopathology may also pose a significant challenge to this objective. Early diagnosis and management are essential and contribute to better survival rates of the patient. To better control this malignancy, such information is expected to be particularly useful in the early detection of possible metastatic lesions and the development of new therapeutic approaches. This article reviews the available information on the early diagnosis and management of CM and discusses such information's potential in facilitating the future prospective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 2×
“The blend has prompted high reaction rates (70%) with a quick response rate, along with an advantage of progression-free survival for 1 year [87, 92].”
BackgroundGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Recently, specific gut microbiota compositions have been found to drive differing responses to immune checkpoint inhibitors in humans [52, 53].”
BackgroundMcArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977 · cited 1×
“PD1 and CTLA4 antibodies (such as pembrolizumab, ipilimumab, and nivolumab), along with specific BRAF inhibitors (dabrafenib and vemurafenib) alone and/or blended with MEK inhibitors (cobimetinib and trametinib), have the promising outcome [84-90].”
BackgroundDelyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318 · cited 1×
“PD1 and CTLA4 antibodies (such as pembrolizumab, ipilimumab, and nivolumab), along with specific BRAF inhibitors (dabrafenib and vemurafenib) alone and/or blended with MEK inhibitors (cobimetinib and trametinib), have the promising outcome [84-90].”
BackgroundZhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2007) · Modern Pathology · doi:10.1038/modpathol.3800750 · Cited by 202 · cited 1×
“Several genetic and immunohistochemical markers associated with the diagnosis of CM were summarized in Table 4 [54-79].”
BackgroundGarrido, A. Q., Wainstein, A. J. A., Brandão, M. P. A., de Vasconcellos Santos, F. A., Bittencourt, F. V., Ledsham, C., & Drummond-Lage, A. P. (2020) · Journal of Cancer Education · doi:10.1007/s13187-020-01735-z · Cited by 15
Cited by
Machine learning and deep learning algorithms for skin cancer classification from dermoscopic images
Bechelli, S., & Delhommelle, J. (2022) · Bioengineering · doi:10.3390/bioengineering9030097 · Cited by 181
“Given that the 5-year survival rate for melanoma can exceed 90% if detected early [4,5], it is crucial to develop highly automated, reliable, and efficient early diagnostic tools.”
Background
Metadata
- Authors
- Naik, P. P.
- Venue
- World Journal of Oncology
- Publisher
- Elmer Press, Inc.
- Published
- 2021
- Volume
- 12
- Issue
- 1
- Pages
- 7-19
- ISSN
- 1920-4531 (ISSN-L)
- 1920-454X
- OpenAlex
- W3129596460
- Cited by
- 177
- References
- 7
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management. https://app.cochat.ai/papers/10.14740/wjon1349
- The paper
- Naik, P. P. (2021). Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management. World Journal of Oncology. https://doi.org/10.14740/wjon1349
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.